159 institutions hold shares in CymaBay Therapeutics Inc. (CBAY), with 273.48k shares held by insiders accounting for 0.40% while institutional investors hold 85.19% of the company’s shares. The shares outstanding are 68.89M, and float is at 65.19M with Short Float at 7.91%. Institutions hold 84.85% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Avoro Capital Advisors LLC with over 10.3 million shares valued at $59.12 million. The investor’s holdings represent 14.95% of the CBAY Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.39 million shares valued at $30.92 million to account for 7.82% of the shares outstanding. The other top investors are Boxer Capital, LLC which holds 4.0 million shares representing 5.81% and valued at over $22.96 million, while Vanguard Group, Inc. (The) holds 4.97% of the shares totaling 3.43 million with a market value of $19.67 million.
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is -15.85% lower on its value in year-to-date trading and has touched a low of $1.21 and a high of $9.06 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CBAY stock was last observed hovering at around $5.15 in the last trading session, with the day’s loss setting it -0.32% off its average median price target of $12.00 for the next 12 months. It is also 75.85% off the consensus price target high of $20.00 offered by 11 analysts, but current levels are 51.7% higher than the price target low of $10.00 for the same period.
Currently trading at $4.83, the stock is -15.20% and -20.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.67 million and changing -6.21% at the moment leaves the stock -17.12% off its SMA200. CBAY registered 185.80% gain for a year compared to 6-month loss of -25.23%. The firm has a 50-day simple moving average (SMA 50) of $5.8400 and a 200-day simple moving average (SMA200) of $6.7997.
The stock witnessed a -17.86% gain in the last 1 month and extending the period to 3 months gives it a -37.76%, and is -14.21% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.78% over the week and 6.64% over the month.
Distance from 52-week low is 299.17% and -46.69% from its 52-week high.
CymaBay Therapeutics Inc. (CBAY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for CymaBay Therapeutics Inc. (CBAY) is a “Buy”. 11 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 11 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
CymaBay Therapeutics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.2.The EPS is expected to shrink by -22.20% this year.
CymaBay Therapeutics Inc. (CBAY) Insider Activity
A total of 0 insider transactions have happened at CymaBay Therapeutics Inc. (CBAY) in the last six months, with sales accounting for 0 and purchases happening 0 times.
CymaBay Therapeutics Inc. (CBAY): Who are the competitors?
The company’s main competitors (and peers) include Bristol-Myers Squibb Company (BMY) that is trading -5.08% down over the past 12 months. Xencor Inc. (XNCR) is 45.11% up on the 1-year trading charts. Short interest in the company’s stock has risen 14.53% from the last report on Dec 30, 2020 to stand at a total of 4.41 million short shares sold with a short interest ratio of 4.24.